{"title":"Editorial: New Insights Into the Aetiopathogenesis of Post-Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next?","authors":"Ayodele Sasegbon,Dipesh H Vasant","doi":"10.1111/apt.70627","DOIUrl":"https://doi.org/10.1111/apt.70627","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"17 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147471426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter: Dose and Donor Matter-Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection.","authors":"D Bogatic,S P Costello,R V Bryant","doi":"10.1111/apt.70625","DOIUrl":"https://doi.org/10.1111/apt.70625","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"37 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147471434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohamed H Eldesouki,Mohammad Kloub,Khaled Elfert,Ahmed Ibrahim,Madhusudan Grover,Swapna Gayam
BACKGROUNDInfection enteritis is associated with the development of irritable bowel syndrome (IBS) and functional dyspepsia.AIMThis study aimed to examine the long-term risk of IBS and functional dyspepsia, and associated health care utilisation following infection enteritis.METHODSWe conducted a retrospective cohort study using TriNetX U.S. Network. Adults with infection enteritis were identified and matched to controls, balancing demographics and comorbidities. Primary outcomes were the risk of incident IBS and functional dyspepsia diagnoses at 1, 5, and 10 years. Secondary outcomes were rates of IBS- and functional dyspepsia-related medications, endoscopy, abdominal imaging, and hospitalizations. Pathogen-specific and multivariate analyses were performed to assess variations in IBS risk.RESULTSAfter matching, 202,244 patients were identified in each study cohort. At 1 year of follow-up, the infection enteritis cohort had higher rates of IBS (RR = 2.35; 95% CI: 2.14-2.59), functional dyspepsia (RR = 2.02; 95% CI: 1.84-2.22), use of IBS-related medications (RR = 1.29; 95% CI: 1.26-1.31), functional dyspepsia-related medications (RR = 1.56; 95% CI: 1.55-1.59), abdominal imaging (RR = 2.42; 95% CI: 2.29-2.54), and Oesophagogastroduodenoscopy/colonoscopy (RR = 1.57; 95% CI: 1.50-1.65). These risks remained significantly higher in the IE cohort at 5 and 10 years. Salmonella/Shigella (RR = 6.48), and Giardia lamblia (RR = 5.05) had the highest risk of developing incident IBS.CONCLUSIONInfection enteritis was associated with increased risk of IBS and functional dyspepsia, rates of related medication use, and greater healthcare utilisation.
{"title":"Cohort Study: Long-Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients.","authors":"Mohamed H Eldesouki,Mohammad Kloub,Khaled Elfert,Ahmed Ibrahim,Madhusudan Grover,Swapna Gayam","doi":"10.1111/apt.70602","DOIUrl":"https://doi.org/10.1111/apt.70602","url":null,"abstract":"BACKGROUNDInfection enteritis is associated with the development of irritable bowel syndrome (IBS) and functional dyspepsia.AIMThis study aimed to examine the long-term risk of IBS and functional dyspepsia, and associated health care utilisation following infection enteritis.METHODSWe conducted a retrospective cohort study using TriNetX U.S. Network. Adults with infection enteritis were identified and matched to controls, balancing demographics and comorbidities. Primary outcomes were the risk of incident IBS and functional dyspepsia diagnoses at 1, 5, and 10 years. Secondary outcomes were rates of IBS- and functional dyspepsia-related medications, endoscopy, abdominal imaging, and hospitalizations. Pathogen-specific and multivariate analyses were performed to assess variations in IBS risk.RESULTSAfter matching, 202,244 patients were identified in each study cohort. At 1 year of follow-up, the infection enteritis cohort had higher rates of IBS (RR = 2.35; 95% CI: 2.14-2.59), functional dyspepsia (RR = 2.02; 95% CI: 1.84-2.22), use of IBS-related medications (RR = 1.29; 95% CI: 1.26-1.31), functional dyspepsia-related medications (RR = 1.56; 95% CI: 1.55-1.59), abdominal imaging (RR = 2.42; 95% CI: 2.29-2.54), and Oesophagogastroduodenoscopy/colonoscopy (RR = 1.57; 95% CI: 1.50-1.65). These risks remained significantly higher in the IE cohort at 5 and 10 years. Salmonella/Shigella (RR = 6.48), and Giardia lamblia (RR = 5.05) had the highest risk of developing incident IBS.CONCLUSIONInfection enteritis was associated with increased risk of IBS and functional dyspepsia, rates of related medication use, and greater healthcare utilisation.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"1 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J L Rueda García,C Suárez Ferrer,I García de la Filia Molina,C Rivas,A Fernández-Clotet,E Céspedes Martínez,C Martínez Cuevas,D C Balderramo,L Arias,H Martínez Lozano,M Vaamonde Lorenzo,M Calafat,D Martín Rodríguez,J X Segarra Ortega,J P Gisbert,E Brunet-Mas,I González-Partida,E Cerrillo Bataller,P Varela Trastoy,K Auquilla Pauta,L Igualada Escribano,M Marquès-Camí,C Muñoz Villafranca,R M de Francisco García,A Elosua González,I Bastón-Rey,J Martínez-Cadilla,L Pardeiro Mariño,O Belén-Galipienso,P Vázquez García,M Latre,P Sendra Rumbeu,A Altadill Mauri,M C López-Martín,Á Ponferrada-Díaz,M R Arribas López,S Rodríguez-Sánchez,P M Wolfe García,M A Ruiz-Ramírez,O Moralejo Lozano,P Sanz Segura,L Madrigal Bayonas,J M Huguet,G Torres,I Alonso Abreu,M D Martín-Arranz,M Mañosa Ciria,Y Zabana,
BACKGROUND AND AIMSPost-operative recurrence (POR) of colonic Crohn's Disease (CD) after segmental (SC) or subtotal colectomy (STC) is scarcely described. Therefore, we aimed to report the rates and predictors of POR in this setting.METHODSMulticentre, nationwide, retrospective study including colonic CD patients undergoing SC or STC. Clinical, endoscopic, radiologic and surgical POR were assessed and POR-free survival was compared between procedures. Cox regression determined predictors of post-colectomy POR. Inverse probability of treatment weighting (IPTW) was carried out for sensitivity analyses.RESULTSA total of 224 patients were included (157 SC, 67 STC). Clinical POR occurred less frequently after SC than after STC (38% vs 63%, p = 0.001), as did endoscopic POR (50% vs 71%, p = 0.012); whereas radiologic and surgical POR rates were similar (p = 0.1 and p = 0.992, respectively). Clinical POR-free survival at 1 and 5 years was higher after SC than after STC (82% and 64.8% vs 67.6% and 39%, log-rank p = 0.001). Endoscopic POR-free survival followed a similar pattern (log-rank p < 0.001). In multivariable Cox regression, SC remained protective against clinical (HR 0.54 [0.36-0.81]) and early endoscopic POR (HR 0.54 [0.35-0.82]). After IPTW, SC was still associated with a significantly lower risk of clinical and endoscopic POR.CONCLUSIONClinical and endoscopic POR rates are significantly lower following SC compared with STC in colonic CD, while radiologic and surgical recurrence rates were similar. SC shows a protective effect regarding clinical and early endoscopic POR. These data support segmental resection of colonic CD when feasible.
背景和目的结肠节段性（SC）或次全结肠切除术（STC）后结肠克罗恩病（CD）术后复发（POR）的报道很少。因此，我们的目的是报告这种情况下POR的发生率和预测因素。方法在全国范围内进行多中心回顾性研究，包括结肠CD患者接受SC或STC。评估临床、内镜、放射学和手术的POR，并比较不同手术的无POR生存率。Cox回归确定结肠切除术后POR的预测因素。采用处理加权逆概率（IPTW）进行敏感性分析。结果共纳入224例患者（SC 157例，STC 67例）。SC后临床POR发生率低于STC后（38% vs 63%, p = 0.001），内镜下POR发生率也低于STC后（50% vs 71%, p = 0.012）；而放射学和外科的POR率相似（p = 0.1和p = 0.992）。SC术后1年和5年临床无por生存率高于STC术后（82%和64.8% vs 67.6%和39%，log-rank p = 0.001）。内镜下无por生存也遵循类似的模式（log-rank p < 0.001）。在多变量Cox回归中，SC对临床（HR 0.54[0.36-0.81]）和早期内镜下POR （HR 0.54[0.35-0.82]）仍有保护作用。IPTW后，SC仍与临床和内镜下POR的风险显著降低相关。结论与结肠CD的STC相比，SC的临床和内镜下POR发生率明显降低，而放射学和手术复发率相似。SC对临床和早期内镜下POR有保护作用。这些数据支持可行的结肠CD节段切除。
{"title":"Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU.","authors":"J L Rueda García,C Suárez Ferrer,I García de la Filia Molina,C Rivas,A Fernández-Clotet,E Céspedes Martínez,C Martínez Cuevas,D C Balderramo,L Arias,H Martínez Lozano,M Vaamonde Lorenzo,M Calafat,D Martín Rodríguez,J X Segarra Ortega,J P Gisbert,E Brunet-Mas,I González-Partida,E Cerrillo Bataller,P Varela Trastoy,K Auquilla Pauta,L Igualada Escribano,M Marquès-Camí,C Muñoz Villafranca,R M de Francisco García,A Elosua González,I Bastón-Rey,J Martínez-Cadilla,L Pardeiro Mariño,O Belén-Galipienso,P Vázquez García,M Latre,P Sendra Rumbeu,A Altadill Mauri,M C López-Martín,Á Ponferrada-Díaz,M R Arribas López,S Rodríguez-Sánchez,P M Wolfe García,M A Ruiz-Ramírez,O Moralejo Lozano,P Sanz Segura,L Madrigal Bayonas,J M Huguet,G Torres,I Alonso Abreu,M D Martín-Arranz,M Mañosa Ciria,Y Zabana, ","doi":"10.1111/apt.70608","DOIUrl":"https://doi.org/10.1111/apt.70608","url":null,"abstract":"BACKGROUND AND AIMSPost-operative recurrence (POR) of colonic Crohn's Disease (CD) after segmental (SC) or subtotal colectomy (STC) is scarcely described. Therefore, we aimed to report the rates and predictors of POR in this setting.METHODSMulticentre, nationwide, retrospective study including colonic CD patients undergoing SC or STC. Clinical, endoscopic, radiologic and surgical POR were assessed and POR-free survival was compared between procedures. Cox regression determined predictors of post-colectomy POR. Inverse probability of treatment weighting (IPTW) was carried out for sensitivity analyses.RESULTSA total of 224 patients were included (157 SC, 67 STC). Clinical POR occurred less frequently after SC than after STC (38% vs 63%, p = 0.001), as did endoscopic POR (50% vs 71%, p = 0.012); whereas radiologic and surgical POR rates were similar (p = 0.1 and p = 0.992, respectively). Clinical POR-free survival at 1 and 5 years was higher after SC than after STC (82% and 64.8% vs 67.6% and 39%, log-rank p = 0.001). Endoscopic POR-free survival followed a similar pattern (log-rank p < 0.001). In multivariable Cox regression, SC remained protective against clinical (HR 0.54 [0.36-0.81]) and early endoscopic POR (HR 0.54 [0.35-0.82]). After IPTW, SC was still associated with a significantly lower risk of clinical and endoscopic POR.CONCLUSIONClinical and endoscopic POR rates are significantly lower following SC compared with STC in colonic CD, while radiologic and surgical recurrence rates were similar. SC shows a protective effect regarding clinical and early endoscopic POR. These data support segmental resection of colonic CD when feasible.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"82 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147393826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amir Gougol,Paul Kwo,William Pike,Mehdi Farokhnia,Gavin Hui,Saurabh Gombar,Babak Mirminachi
BACKGROUNDMetabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapies for MetD, including type 2 diabetes mellitus (T2DM) and obesity. Recent studies suggested potential beneficial effects of GLP-1RA to decrease addictive behaviours in AUD. We evaluated the outcomes of GLP-1RA therapy compared with FDA-approved pharmacotherapies for AUD, including naltrexone, acamprosate, and disulfiram, in patients with dual risk factors of MetD and AUD.METHODSWe conducted a retrospective cohort study of patients at Stanford Health Care (2017-2025). Eligible patients had a concurrent diagnosis of alcohol-related complications meeting criteria for AUD and MetD, including obesity (BMI > 25) and/or a history of T2DM with HbA1c > 5.7. Those with advanced liver disease within 1 year of diagnosis were excluded. Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD. Propensity score matching was employed to reduce the effects of confounding factors.RESULTSIn total, 1946 patients were diagnosed concurrently with AUD and MetD. Of them, 274 patients were exposed to GLP-1RA, 1272 to naltrexone, 232 to acamprosate, and 168 to disulfiram. Patients were followed for an average of 1341 days. Patients exposed to GLP-1RA had higher BMI (35.5 vs. 30.1) and more T2DM (66% vs. 14%). GLP-1RA therapy was associated with lower 1-year AUD relapse [IRR 0.55, 95% CI 0.42-0.73; p < 0.01], greater BMI reduction (-1.3 vs. -0.3; p = 0.004), and HbA1c improvement (-1.0 vs. +0.1; p = 0.02). The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09]. Mortality was similar.CONCLUSIONSGLP-1RAs are a promising option for patients with concurrent MetD and AUD, improving relapse rates and metabolic outcomes compared with currently FDA-approved pharmacotherapies for AUD. Trends toward better liver outcomes support further prospective evaluation.
背景：代谢功能障碍（MetD）和酒精使用障碍（AUD）经常共存，是脂肪变性肝病的协同危险因素。胰高血糖素样肽-1受体激动剂（GLP-1RAs）是MetD的既定治疗方法，包括2型糖尿病（T2DM）和肥胖。最近的研究表明，GLP-1RA对减少AUD成瘾行为有潜在的有益作用。我们评估了GLP-1RA治疗与fda批准的AUD药物治疗（包括纳曲酮、阿坎普罗酸和双硫仑）在具有MetD和AUD双重危险因素的患者中的结果。方法对2017-2025年斯坦福医疗中心的患者进行回顾性队列研究。符合条件的患者同时诊断为酒精相关并发症，符合AUD和MetD标准，包括肥胖（BMI为bbb25）和/或T2DM病史，HbA1c为> 5.7。排除诊断1年内有晚期肝病的患者。与fda批准的AUD药物治疗相比，暴露组包括GLP-1RA治疗（西马鲁肽或替西帕肽）≥6个月。采用倾向得分匹配来减少混杂因素的影响。结果共有1946例患者同时诊断为AUD和med。其中，274例患者暴露于GLP-1RA， 1272例暴露于纳曲酮，232例暴露于阿坎普罗酸，168例暴露于双硫仑。患者的随访时间平均为1341天。暴露于GLP-1RA的患者有更高的BMI（35.5对30.1）和更多的T2DM（66%对14%）。GLP-1RA治疗与较低的1年AUD复发率相关[IRR 0.55, 95% CI 0.42-0.73；p < 0.01]，更大的BMI降低（-1.3 vs. -0.3; p = 0.004）和HbA1c改善（-1.0 vs. +0.1; p = 0.02）。失代偿期肝硬化发生率降低，但无统计学意义[HR 0.52, p = 0.09]。死亡率相似。结论：与目前fda批准的AUD药物治疗相比，sglp - 1ras对于同时患有med和AUD的患者是一个很有希望的选择，可以改善复发率和代谢结果。改善肝脏预后的趋势支持进一步的前瞻性评价。
{"title":"Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.","authors":"Amir Gougol,Paul Kwo,William Pike,Mehdi Farokhnia,Gavin Hui,Saurabh Gombar,Babak Mirminachi","doi":"10.1111/apt.70596","DOIUrl":"https://doi.org/10.1111/apt.70596","url":null,"abstract":"BACKGROUNDMetabolic dysfunction (MetD) and alcohol use disorder (AUD) frequently coexist as synergistic risk factors for steatotic liver disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapies for MetD, including type 2 diabetes mellitus (T2DM) and obesity. Recent studies suggested potential beneficial effects of GLP-1RA to decrease addictive behaviours in AUD. We evaluated the outcomes of GLP-1RA therapy compared with FDA-approved pharmacotherapies for AUD, including naltrexone, acamprosate, and disulfiram, in patients with dual risk factors of MetD and AUD.METHODSWe conducted a retrospective cohort study of patients at Stanford Health Care (2017-2025). Eligible patients had a concurrent diagnosis of alcohol-related complications meeting criteria for AUD and MetD, including obesity (BMI > 25) and/or a history of T2DM with HbA1c > 5.7. Those with advanced liver disease within 1 year of diagnosis were excluded. Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD. Propensity score matching was employed to reduce the effects of confounding factors.RESULTSIn total, 1946 patients were diagnosed concurrently with AUD and MetD. Of them, 274 patients were exposed to GLP-1RA, 1272 to naltrexone, 232 to acamprosate, and 168 to disulfiram. Patients were followed for an average of 1341 days. Patients exposed to GLP-1RA had higher BMI (35.5 vs. 30.1) and more T2DM (66% vs. 14%). GLP-1RA therapy was associated with lower 1-year AUD relapse [IRR 0.55, 95% CI 0.42-0.73; p < 0.01], greater BMI reduction (-1.3 vs. -0.3; p = 0.004), and HbA1c improvement (-1.0 vs. +0.1; p = 0.02). The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09]. Mortality was similar.CONCLUSIONSGLP-1RAs are a promising option for patients with concurrent MetD and AUD, improving relapse rates and metabolic outcomes compared with currently FDA-approved pharmacotherapies for AUD. Trends toward better liver outcomes support further prospective evaluation.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"26 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147393833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter: Eating Disorders in Inflammatory Bowel Disease-Are We Asking the Right Questions?","authors":"Jacoba C van Wees,Robert D Little,Sarah L Melton","doi":"10.1111/apt.70582","DOIUrl":"https://doi.org/10.1111/apt.70582","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"45 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147383285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisa Pinto, Filippo Pelizzaro, Laura Bucci, Martina Gambato, Fabio Farinati, Edoardo G Giannini, Francesco Paolo Russo
{"title":"Letter: Improving the Interpretability and Portability of Tumour Burden Score-Based Prediction of Extrahepatic Progression After Transarterial Chemoembolisation (TACE)-Author's Reply.","authors":"Elisa Pinto, Filippo Pelizzaro, Laura Bucci, Martina Gambato, Fabio Farinati, Edoardo G Giannini, Francesco Paolo Russo","doi":"10.1111/apt.70587","DOIUrl":"https://doi.org/10.1111/apt.70587","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ryan Yanzhe Lim,Glenn Jun Kit Ho,Mirudhula Gnanavelou,Eunice Xiang-Xuan Tan
{"title":"Letter: Liver Transplantation Outcomes for Alcohol-Associated Liver Disease-Commentary on an Individual Patient Data Meta-Analysis and Future Research Directions. Authors' Reply.","authors":"Ryan Yanzhe Lim,Glenn Jun Kit Ho,Mirudhula Gnanavelou,Eunice Xiang-Xuan Tan","doi":"10.1111/apt.70607","DOIUrl":"https://doi.org/10.1111/apt.70607","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"33 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147381290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：